Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CGON NASDAQ:CNTA NASDAQ:HROW NASDAQ:MIRM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCGONCG Oncology$67.18-0.8%$65.25$21.00▼$73.56$5.96B0.411.04 million shs743,655 shsCNTACentessa Pharmaceuticals$39.67-0.1%$33.17$10.95▼$40.26$5.92B1.132.43 million shs736,556 shsHROWHarrow$40.50+0.7%$38.93$21.12▼$54.85$1.50B0.34494,569 shs442,215 shsMIRMMirum Pharmaceuticals$105.81+0.0%$93.79$40.00▼$110.49$6.45B0.52672,657 shs1.18 million shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCGONCG Oncology0.00%-0.82%-1.79%+26.08%+128.12%CNTACentessa Pharmaceuticals0.00%+0.15%-0.30%+55.30%+190.74%HROWHarrow0.00%-1.23%+15.83%-13.33%+58.34%MIRMMirum Pharmaceuticals0.00%+4.38%+2.51%-8.46%+120.94%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCGONCG Oncology$67.18-0.8%$65.25$21.00▼$73.56$5.96B0.411.04 million shs743,655 shsCNTACentessa Pharmaceuticals$39.67-0.1%$33.17$10.95▼$40.26$5.92B1.132.43 million shs736,556 shsHROWHarrow$40.50+0.7%$38.93$21.12▼$54.85$1.50B0.34494,569 shs442,215 shsMIRMMirum Pharmaceuticals$105.81+0.0%$93.79$40.00▼$110.49$6.45B0.52672,657 shs1.18 million shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCGONCG Oncology0.00%-0.82%-1.79%+26.08%+128.12%CNTACentessa Pharmaceuticals0.00%+0.15%-0.30%+55.30%+190.74%HROWHarrow0.00%-1.23%+15.83%-13.33%+58.34%MIRMMirum Pharmaceuticals0.00%+4.38%+2.51%-8.46%+120.94%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCGONCG Oncology 2.77Moderate Buy$79.5518.41% UpsideCNTACentessa Pharmaceuticals 2.21Hold$40.702.60% UpsideHROWHarrow 2.64Moderate Buy$69.8672.49% UpsideMIRMMirum Pharmaceuticals 2.93Moderate Buy$125.2518.37% UpsideCurrent Analyst Ratings BreakdownLatest HROW, CNTA, MIRM, and CGON Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/5/2026MIRMMirum Pharmaceuticals Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$130.00 ➝ $140.005/4/2026MIRMMirum Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$150.00 ➝ $175.004/29/2026MIRMMirum Pharmaceuticals Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$125.00 ➝ $130.004/28/2026MIRMMirum Pharmaceuticals Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$95.00 ➝ $112.004/27/2026MIRMMirum Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$130.00 ➝ $150.004/27/2026CGONCG Oncology Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$73.00 ➝ $79.004/22/2026HROWHarrow Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/21/2026MIRMMirum Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026MIRMMirum Pharmaceuticals Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$132.004/20/2026CGONCG Oncology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026CNTACentessa Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 5/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCGONCG Oncology$4.04M1,463.49N/AN/A$9.33 per share7.20CNTACentessa Pharmaceuticals$15M394.66N/AN/A$3.92 per share10.12HROWHarrow$272.30M5.54$0.87 per share46.51$1.41 per share28.72MIRMMirum Pharmaceuticals$521.31M12.38$0.05 per share2,075.16$6.12 per share17.29Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCGONCG Oncology-$160.99M-$2.07N/AN/AN/AN/A-22.87%-21.82%5/7/2026 (Estimated)CNTACentessa Pharmaceuticals-$197.53M-$1.47N/AN/AN/AN/A-50.66%-36.65%5/13/2026 (Estimated)HROWHarrow-$5.14M-$0.17N/A16.40N/A-1.89%36.51%5.06%5/11/2026 (Estimated)MIRMMirum Pharmaceuticals-$23.36M-$0.48N/A813.92N/A-4.48%-8.53%-3.07%5/6/2026 (Estimated)Latest HROW, CNTA, MIRM, and CGON EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026CNTACentessa Pharmaceuticals-$0.38N/AN/AN/AN/AN/A5/11/2026Q1 2026HROWHarrow-$0.3538N/AN/AN/A$52.43 millionN/A5/7/2026Q1 2026CGONCG Oncology-$0.58N/AN/AN/A$0.45 millionN/A5/6/2026Q1 2026MIRMMirum Pharmaceuticals-$0.40N/AN/AN/A$148.20 millionN/A3/31/2026Q4 2025CNTACentessa Pharmaceuticals-$0.38-$0.48-$0.10-$0.48$0.77 millionN/A2/27/2026Q4 2025CGONCG Oncology-$0.61-$0.51+$0.10-$0.51N/A$2.32 million2/25/2026Q4 2025MIRMMirum Pharmaceuticals$0.02-$0.11-$0.13-$0.12$141.78 million$148.93 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCGONCG OncologyN/AN/AN/AN/AN/ACNTACentessa PharmaceuticalsN/AN/AN/AN/AN/AHROWHarrowN/AN/AN/AN/AN/AMIRMMirum PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCGONCG OncologyN/A24.6324.58CNTACentessa Pharmaceuticals0.218.578.57HROWHarrow4.672.202.06MIRMMirum Pharmaceuticals0.982.672.55Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCGONCG Oncology26.56%CNTACentessa Pharmaceuticals82.01%HROWHarrow72.76%MIRMMirum PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipCGONCG Oncology4.80%CNTACentessa Pharmaceuticals7.09%HROWHarrow12.80%MIRMMirum Pharmaceuticals22.87%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCGONCG Oncology6188.01 million83.79 millionOptionableCNTACentessa Pharmaceuticals200149.23 million138.65 millionOptionableHROWHarrow18037.27 million32.50 millionOptionableMIRMMirum Pharmaceuticals14060.98 million47.03 millionOptionableHROW, CNTA, MIRM, and CGON HeadlinesRecent News About These CompaniesMirum Pharmaceuticals Announces Primary Endpoint Met in VISTAS Study of Volixibat in Patients with Primary Sclerosing CholangitisMay 5 at 9:24 AM | rutlandherald.comRMIRM stock clocks best day in 4.5 months on liver disease trial data: Retail eyes buyout at a premiumMay 5 at 9:24 AM | msn.comMirum Pharmaceuticals (NASDAQ:MIRM) Sets New 52-Week High After Analyst UpgradeMay 5 at 1:16 AM | marketbeat.comMirum Pharmaceuticals, Inc. (MIRM) Discusses Topline Clinical Results in Primary Sclerosing Cholangitis and Hepatitis Delta TranscriptMay 4 at 9:01 PM | seekingalpha.comMirum Pharmaceuticals (NASDAQ:MIRM) Shares Gap Down - What's Next?May 4 at 2:10 PM | marketbeat.comMirum's rare liver disease drug meets main goal in mid-stage studyMay 4 at 2:04 PM | reuters.comMirum Pharmaceuticals Says Volixibat Phase IIb VISTAS Hits Endpoint, Cuts PSC Itch vs PlaceboMay 4 at 1:20 PM | marketbeat.comHC Wainwright Forecasts Strong Price Appreciation for Mirum Pharmaceuticals (NASDAQ:MIRM) StockMay 4 at 12:41 PM | marketbeat.comMirum Pharmaceuticals Rally Reflects Confidence In Late-Stage Liver Disease AssetsMay 4 at 12:09 PM | benzinga.comMirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Given Consensus Recommendation of "Moderate Buy" by AnalystsMay 4 at 4:08 AM | americanbankingnews.comMirum Pharmaceuticals to Host Investor Call to Share Topline Results from the VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis on May 4, 2026May 3 at 5:00 PM | businesswire.comPictet Asset Management Holding SA Purchases 35,997 Shares of Mirum Pharmaceuticals, Inc. $MIRMApril 30, 2026 | marketbeat.comMirum Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026April 29, 2026 | finance.yahoo.comMirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 ReleaseApril 29, 2026 | zacks.comMirum Pharmaceuticals (NASDAQ:MIRM) Price Target Raised to $130.00 at Stifel NicolausApril 29, 2026 | marketbeat.comMirum HDV Trial Success Adds New Late Stage Growth OptionApril 29, 2026 | finance.yahoo.comAssessing Mirum Pharmaceuticals (MIRM) Valuation After Strong Shareholder Returns And Rare Disease Pipeline ProgressApril 29, 2026 | finance.yahoo.comHC Wainwright Has Pessimistic Outlook of MIRM Q1 EarningsApril 29, 2026 | marketbeat.comMirum Pharmaceuticals (MIRM) Expected to Announce Quarterly Earnings on WednesdayApril 29, 2026 | marketbeat.comMirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Given Average Rating of "Moderate Buy" by AnalystsApril 29, 2026 | marketbeat.comMirum Pharmaceuticals (NASDAQ:MIRM) Price Target Raised to $112.00 at Robert W. BairdApril 28, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHROW, CNTA, MIRM, and CGON Company DescriptionsCG Oncology NASDAQ:CGON$67.18 -0.52 (-0.77%) Closing price 04:00 PM EasternExtended Trading$67.18 -0.01 (-0.01%) As of 07:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.Centessa Pharmaceuticals NASDAQ:CNTA$39.67 -0.03 (-0.08%) Closing price 04:00 PM EasternExtended Trading$39.66 -0.01 (-0.01%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.Harrow NASDAQ:HROW$40.50 +0.30 (+0.75%) Closing price 04:00 PM EasternExtended Trading$40.49 -0.01 (-0.02%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.Mirum Pharmaceuticals NASDAQ:MIRM$105.81 +0.02 (+0.02%) Closing price 04:00 PM EasternExtended Trading$105.81 0.00 (0.00%) As of 07:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir Drops After a Blowout Q1—What Investors Should Know Shopify’s Valuation Crisis Creates Opportunity in 2026 onsemi Stock Dips After Earnings: Why the Dip Is Buyable TSLA: 3 Reasons the Stock Could Hit $400 in May Nebius Breaks Out to All-Time Highs—Here's What's Driving It. 3 Reasons Analysts Love DexCom The Great Chip Divide: AI Chip War Pivots from Hype to Execution Atomic Dividends: Big Tech's New Energy Bet Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
